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ABSTRACT 
 
The negative health and economic impacts of neurodegenerative diseases on Americans 
is astounding and accelerating with an aging population. The Alzheimer’s Association reports 
that 5.7 million Americans suffer from Alzheimer’s disease (AD), a number which is expected to 
increase to 14 million by 2050. In economic terms, AD and other neurodegenerative disorders 
will cost the US over $275 billion in 2018, rising to over $1 trillion annually by 2050. AD causes 
gross brain atrophy and is most damaging throughout the cortex and the hippocampus, regions 
required for higher cognitive function and memory. AD presents as tangles within neurons 
composed of the tau protein, and plaques outside of neurons consisting of amyloid beta. 
Aggregates have been clearly shown to have associated toxicity. 
The past three decades of drug development targeting amyloid beta, an aggregating 
protein responsible for plaques seen in AD, has failed and currently we have no treatments 
beyond ameliorative options. Therapeutic alternatives with novel targets are desperately needed 
in our fight against AD. Therefore, the ultimate goal of this research is to identify novel enzymes 
involved in aggregation and provide a potential therapeutic option for neurodegeneration capable 
of lessening tau tangle burden, protecting against the loss of neurons, and preventing cognitive 
decline.  
In AD, both amyloid beta and tau proteins aberrantly aggregate and promote neuronal 
loss, gross brain tissue degeneration, and cognitive decline. Although the interplay between these 
two proteins is not well understood, it is clear that targeting amyloid beta has not worked thus far 
despite over 100 phase III clinical trials targeting amyloid beta. Additionally, it has been 
vii 
 
repeatedly shown that tau neurofibrillary tangles are correlated with disease severity and not 
amyloid beta plaques. Finally, tau tangles are present in many other neurodegenerative dementia 
disorders termed tauopathies including progressive supranuclear palsy, corticobasal 
degeneration, Pick’s disease, and frontotemporal lobar dementia. Strategies that target tau have a 
higher chance of success over amyloid beta, and if a therapeutic is found will have a broad 
impact as tau is involved in so many other devastating neurodegenerative diseases. 
Here we show that a human peptidyl prolyl-isomerase (PPIase), cyclophilin 40 (CyP40), 
dissolves fibrillized tau amyloid fibril in recombinant protein assays, in a human cell model, and 
in a mouse brain overexpressing human tau. PPIases play an important role in normal cell 
physiology as catalysts of protein folding at structurally important proline residues for both 
newly synthesized proteins and in conformational changes for molecular switches. Intrinsically 
disordered amyloid-forming proteins like tau have proline-rich regions which may regulate 
aggregation propensity. Our work reveals human CyP40 protein, on its own, possesses 
remarkable disaggregase activity towards amyloidogenic tau and α-synuclein through interaction 
with proline residues. CyP40 disaggregase activity is ATP-independent, using its peptidyl-prolyl 
isomerase activity and untangles amyloid fibrils in vitro. Additionally, CyP40 decreases both tau 
fibril and oligomer accumulation in a transgenic mouse tauopathy model and delivery of CyP40 
to neurons early in the pathogenic progression of the mouse model results in significant 
improvements in learning and memory as assessed by radial arm water maze and fear 
conditioning paradigms. This demonstrates a novel disaggregation mechanism for CyP40 
making it a potential therapeutic target for neurodegenerative disease. 
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CHAPTER ONE1: 
 
AGGREGATION AND NEURODEGENERATIVE DISEASE 
 
1.1 Abstract 
 
The misbehavior of key proteins results in aberrant misfolding or misassembly and leads to 
neuronal loss, producing motor or cognitive impairments found in many neurological disorders, 
including Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis 
(ALS), and Huntington’s disease (HD). These amyloid aggregates are distinguished by 
characteristic β-sheet structures that can form long fibrils as well as recruit and convert protein 
that has not yet misfolded. Indeed, because amyloid formation results in a heterogeneous mix of 
many oligomeric, prefibrillar and fibrillar structures, determining the toxic aggregated species 
has been difficult, and current therapeutics have failed to prevent the pathology caused by these 
proteins.  Here we provide background on protein folding regulatory processes as well as 
illustrate certain determinants for protein misfolding. We will also describe current hypotheses 
on how protein aggregates cause cellular stress and neurodegeneration and provide an overview 
of new early detection and therapeutic strategies.  
____________________ 
1Portions of this work were previously published (Baker, J.D. et al., 2018) and are used with permission of 
the publisher. 
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1.2 Introduction  
Neurodegeneration is a result of modification and actions key proteins that are aberrantly 
misfolded or misassembled, leading to neuronal loss producing motor or cognitive impairments. 
Misfolding and subsequent aggregation of proteins is linked to many neurological disorders, 
including Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis 
(ALS), and Huntington’s disease (HD), to name a few. Generally, these protein aggregates form 
a special structure known as amyloid, which has the distinguishing characteristic of containing β-
sheet structures that can aggregate into long fibrils as well as recruit and convert protein that has 
not yet misfolded. How the formation of amyloid aggregates leads to neuronal dysfunction and 
neuron loss despite cellular machinery and processes evolved to ensure proper protein folding 
and regulation is an area of active research1. Indeed, because amyloid formation results in a 
heterogeneous mix of many oligomeric, prefibrillar and fibrillar structures, determining the toxic 
aggregated species has been difficult, and current therapeutics have failed to prevent the 
pathology caused by these proteins.  This chapter will provide background on protein folding 
regulatory processes as well as illustrate certain determinants for protein misfolding. We will 
also describe current hypotheses on how protein aggregates cause cellular stress and 
neurodegeneration and provide an overview of new early detection and therapeutic strategies. 
1.3  Discussion 
1.3.1 Roles for protein folding, modification and degradation 
 Proteins are essential macromolecules of all living cells. Their functions are crucial and 
diverse, ranging from key structural components such as keratins, which form external protective 
layers of all land vertebrates, and tubulin, which forms the eukaryotic cytoskeleton and plays a 
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central role in neuronal transport2, to various enzymes catalyzing a multitude of biological 
reactions, such as acetylcholinesterase, a key protein within the synaptic cleft. Mammalian 
immune defense relies on antibody proteins, while cellular, tissue, and organ messaging depends 
on growth hormone proteins for communication3. Obviously, these listed examples represent 
only a miniscule fraction of the immense universe of protein functions. The functional diversity 
of proteins arises from the multitude of polypeptide chains, whose sequences are uniquely 
assembled from a set of 20 major amino acids. Alternative splicing and RNA editing ensures 
diversification of mRNA and plays an important role in increasing the assortment of functional 
proteins encoded in the genome. Some proteins are folded into unique structures, whereas others 
exist as dynamic conformational ensembles. Biological activities of many proteins require 
further assembly of individual chains to large functioning protein complexes. Furthermore, 
synthesized proteins can be further diversified via various chemical modifications introduced by 
other proteins4. These so-called post-translational modifications (PTMs) are important for 
regulating the wide spectrum of protein functions that play important roles in various biological 
processes, ranging from cell signaling to translocation of newly synthesized proteins. In fact, 
although DNA typically encodes 20 primary amino acids, proteins contain more than 140 
different residues, because of various PTMs.  As illustrated below, abnormal PTMs can lead to 
neurodegeneration. Phosphorylation, the transfer of a phosphoryl group to an amino acid 
mediated by a variety of kinases, is the most common PTM. Phosphorylation plays a key role as 
a biochemical “switch” for some proteins, for instance activating or deactivating certain 
enzymes. A host of neurodegenerative diseases known as tauopathies may arise after the 
abnormal hyperphosphorylation of tau, a protein known to stabilize axonal microtubules5. 
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Acetylation, another common PTM where acetyl groups are covalently linked to an N-terminal 
amino group or lysine residue, generally results in changes in the stability of proteins. Histone 
acetylases (HATs) and histone deacetylases (HDACs) control the balance of acetylation of 
specific substrates. When the cellular environment changes and a neuron loses acetylation 
homeostasis, due to a change in HAT:HDAC equilibrium, neurodegenerative disease can 
result6,7. Another common PTM, glycosylation, or the addition of carbohydrates to amino acid 
residues, is crucial to the proper folding and translocation of many cell surface and secreted 
proteins8. Traumatic brain injury (TBI) often results in an altered pattern of glycosylated amyloid 
precursor protein, which may be linked to its pathological clinical presentation in the form of 
cerebral plaques9,10. 
In addition to PTMs playing a role in proper folding of nascent proteins and regulation of 
protein function, a class of proteins known as molecular chaperones assist in forming the correct 
three-dimensional structure of proteins and help to assemble large protein complexes11. Many 
molecular chaperones are activated in response to cellular stress, such as elevated temperature or 
changes in pH or salt concentration12. Cellular stress, like heat, causes a much higher incidence 
of misfolding, which may lead to protein aggregation. In humans, some of the more important 
cellular chaperones use ATP as an energy source to actively support the folding or unfolding of 
proteins and are termed foldases or unfoldases13-15. For example, heat shock protein 70 (Hsp70), 
a chaperone expressed in response to causes of neuronal stress, including stroke and 
neurodegenerative disease, may play an important role in the suppression of aggregation and 
resulting toxicity of some neuropathic proteins16,17. Some other chaperones, like the small heat 
shock proteins αB-crystallin and Hsp27, are ATP- independent and do not actively fold proteins, 
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but rather hold proteins in certain conformations and are referred to as holdases18. These small 
heat shock proteins have been shown to reduce toxicity caused by α-synuclein in Parkinson’s 
disease19. One of the more exciting recent discoveries is that of a chaperone complex of Hsp70, a 
DnaJ co-chaperone, and the nucleotide exchange factor Hsp110, which work in concert and 
harnesses energy from ATP to physically pull apart and disassemble amyloid fibrils. This 
complex disassembles α-synuclein amyloid fibrils leading to a non-toxic end-product20. Research 
into harnessing the power of this human disaggregase machinery to disentangle pathological 
amyloids is just beginning but presents a novel therapeutic approach.  
Protein homeostasis (or proteostasis) is required for cellular health and is controlled not 
only by the rate of synthesis of proteins, their proper folding and trafficking, PTMs and the 
action of molecular chaperones, but also by regulated degradation21,22. Degradation processes 
within the proteostasis network include the ubiquitin-proteasome system (UPS), chaperone 
mediated autophagy (CMA) and macroautophagy23. Misfolded proteins can be marked for 
proteosomal degradation by covalent tagging with chains of ubiquitin protein. A downregulation 
of the UPS is associated with progressive onset of several neurodegenerative diseases, and it is 
thought that aggregated proteins can physically interfere with the proteasome machinery to 
reduce its activity24,25. Autophagy refers to the cellular sequestration of proteins into lysosomes, 
an organelle containing hydrolytic enzymes capable of degrading diverse proteins. Like the UPS, 
down regulation or genetic inactivation of autophagy has been linked to numerous degenerative 
diseases26,27.  
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 The remainder of this chapter will focus on the precise causes of the misfolding of 
proteins, how they result in toxic oligomeric and amyloid assemblies, and current explanations 
for how these proteins may cause disease. 
1.3.2 What is protein misfolding and why does it occur? 
 Misfolding of certain proteins leads to neurodegenerative disease, due to loss of native 
protein function or a gain of deleterious function, the latter resulting from aggregation into toxic 
structures28-31. This chapter will focus on protein aggregation as a toxic gain of function 
phenomenon associated with many neurological disorders. 
 Generally, in the case of structurally ordered proteins, nascent polypeptide chains fold 
into properly functioning three-dimensional structures, either spontaneously or with the 
assistance of molecular chaperones. Resulting structures can be further tuned with the help of 
post-translational modifications. Structural integrity of a folded protein is maintained via an 
interplay of weak conformational forces (such as hydrophobic interactions, hydrogen bonds, van 
der Waals interactions and electrostatic interactions) opposing the action of conformational 
entropy. Folded globular proteins are characterized by structures where hydrophobic residues are 
generally buried deep within the protein core and amino acid side chains are engaged in multiple 
interactions to maintain conformation.  However, because of fluctuating environmental 
conditions, such as changes in pH or temperature, native state proteins may partially unfold, and 
the resulting intermediates may begin to aggregate. Misfolding and aggregation can also be 
triggered by point mutations, aberrant PTMs, and many other factors. Pathological proteins 
undergo a series of steps from their native monomeric form to multi-unit aggregates, typically 
rich in β-sheet structure. During this conformational change from properly folded to misfolded 
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and aggregated forms, often involving a shift from native α-helical secondary structure to β-sheet 
structure, some key hydrophobic residues, originally buried within the protein core, are 
exposed23,32. These hydrophobic residues located on the protein surface cause inter-chain 
attraction manifested in multiple protein monomers coming together to form aggregates. Often, 
the assembly of these β-sheet-rich structures has a fibrillar morphology, and the resulting 
aggregated forms are termed amyloid fibrils. One should keep in mind though that, in addition to 
amyloid fibrils, many other types of pathological protein aggregates can be formed, ranging from 
various assemblies of soluble oligomers and protofibrils, to amorphous aggregates and 
spherulites33-36.  
 Amyloid fibrils have been associated with more than 30 human diseases, including 
several neurodegenerative disorders as shown in Table 1.137-39. Fibrils (or at least their core) are 
normally composed of polypeptides taking on a β-sheet secondary structure, which then self-
associate to form long fibers40,41. Using atomic force microscopy and transmission electron 
microscopy, fibrils have been shown to consist of a cross-β-sheet secondary structure within the 
core of the fibrils, where the parallel chains of β-stranded peptides are arranged in an orientation 
perpendicular to the axis of the fiber and linked by an array of inter-backbone hydrogen 
bonds42,43. This structure is incredibly resistant to cellular degradation mechanics as well as 
experimental means of protein structure disruption44-47. Amyloid may consist of hundreds and 
often thousands of the original monomeric protein subunits, resulting in large bodies visible by 
microscopy within neurons and brain tissue.  
 Although amyloid fibrils are the most commonly detected form of aggregation, these 
pathogenic proteins form a heterogeneous mixture of oligomers, protofibrils and fibrils48,49. The 
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structures and associated pathology of these assemblies is of great interest as we look for 
multiple toxic species responsible for the associated neurological diseases. Generally, the end-
products of aggregation are insoluble fibrillar amyloid aggregates; however there are many 
intermediary structures along the pathways of aggregation50-53.  Because the aggregate structures 
of proteins like Aβ and tau are disordered and consist of a heterogeneous population of species, 
traditional methods to study structure, such as x-ray crystallography and nuclear magnetic 
resonance, has not yielded high-resolution structures for many smaller aggregates. However, 
recent advances in solid-state NMR have given us key insights into aggregate structures 
specifically in regard to Aβ52,54,55.  
1.3.3 Pathological misfolding of intrinsically disordered and mutant proteins 
Many pathological amyloidogenic proteins that cause neurodegeneration are intrinsically 
disordered. That is, they present not as classical globular three-dimensional structures, but as a 
highly dynamic conformational ensembles56,57. The flexibility of intrinsically disordered proteins 
allows them to assume numerous conformations and increases binding affinity for a much larger 
range of substrates compared to fixed-conformation globular proteins. However, the flexibility 
and lack of a three-dimensional structure, along with an enhanced propensity to be post-
translationally modified and engaged in multiple physiological and pathological interactions 
makes some of these proteins more prone to aggregation and amyloid formation58,59. Intrinsically 
disordered proteins which aggregate in neurological diseases include the microtubule binding 
protein tau and amyloid beta (Aβ)58,60,61, both involved in Alzheimer’s disease, as well as α-
synuclein, which aggregates to form Lewy bodies in Parkinson’s disease pathology62,63.   
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Meanwhile other misfolded proteins involved in neurodegeneration develop a propensity 
for misfolding resulting from a genetic expansion of nucleotide repeats. Expanded CAG repeats 
in the coding region of certain genes results in expanded polyglutamine (PolyQ) tracts within the 
translated protein, which have a propensity to misfold into β-sheet-containing amyloids64.  For 
example, Huntington’s disease and spinocerebellar ataxias are caused by expanded polyQ tracts 
within the huntingtin or ataxin proteins65.  Additionally, expanded nucleotide repeat sequences in 
the noncoding region of the C9orf72 gene have been linked to frontotemporal dementia and 
amyotrophic lateral sclerosis66.  This nucleotide repeat expansion becomes translated in the 
absence of a start codon into a mixture of 5 aggregating dipeptide repeat (DPR) proteins 
translated from all 6 reading frames67.   
 Although it has been challenging to study the mechanisms of self-assembly of these 
pathological proteins by experimentation, with the help of molecular dynamic simulations and 
advanced biochemical techniques, a more robust picture of what drives aggregate formation is 
emerging. Monitoring fibril growth with a quartz crystal oscillator has revealed that the native 
state of these proteins is thermodynamically more stable than the amyloid state as long as a 
critical concentration of amyloid is not reached40,61. Once a critical concentration of amyloid is 
present in the cell, the native state will inevitably and spontaneously be driven by 
thermodynamics toward the amyloid state unless cellular mechanisms prevent the transition. 
Experiments using small amyloid-forming fragments of several proteins have given insights into 
the kinetics of amyloid formation. Three kinetic stages occur in amyloid formation. Firstly, 
nucleation of monomers results in the formation of a metastable critical nucleus, which can shift 
the protein into a growth phase. This growth phase consists of rapid assembly of oligomers into 
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protofibrils which self-associate.  Ultimately, a final dynamic stabilization phase is reached, in 
which mature fibrils are formed68,69.  
 The triggers that start the aggregation process vary and range from post-translational 
modifications to changes in environmental factors within the cell. Additionally, certain amino 
acid changes due to genetic variation within aggregation-prone proteins increase the propensity 
for self-assembly into amyloid70-73.  It should be noted that intrinsically ordered proteins 
“breathe”, that is they have an inherent fluctuation in conformation which may transiently expose 
residues normally not exposed to the cellular environment, increasing chances for 
aggregation74,75, environmental stressors like pH changes, pressure changes, salt concentration 
changes, and temperature changes can drive partial unfolding of proteins and cause an 
aggregation cascade76-80. 
Under normal cellular conditions, environmental factors are kept relatively constant, and 
other factors may be predominantly responsible for triggering amyloidogenesis. A recognized 
trigger of amyloidogenesis of tau protein is its hyperphosphorylation, indicating suggesting 
regulation via cell-signaling pathways. Tau is rich in phosphorylation sites and is regulated by a 
number of kinases. When tau is heavily phosphorylated, its association with microtubules is 
disrupted. This disruption from microtubules facilitates self-association and the formation of 
aggregates. 
1.3.4 How do misfolded proteins and aggregates cause neurodegeneration? 
 Increasing evidence supports oligomers as the causative toxic species in a number of 
neurodegenerative disorders, whereby fibril generation is thought to be a protective mechanism 
in neurons, sequestering the smaller toxic aggregates81-83. It is well known that Aβ aberrantly 
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accumulates in Alzheimer’s disease (AD); however, the presence of deposited extracellular Aβ 
plaques do not generally correlate well with disease progression84, and many healthy brains carry 
an Aβ plaque burden without associated cognitive deficits. This has led to the hypothesis that a 
smaller soluble aggregated form of Aβ is somehow pathogenic. In a mouse model of tauopathy, 
turning off tau expression halted neuronal loss and prevented cognitive decline, even though 
neurofibrillary tangles remained present and further accumulated85, providing evidence for a 
soluble oligomeric intermediate as the toxic species. Additionally, TDP-43, a protein associated 
with ALS, has been shown to form a heterogeneous population of oligomers, and these 
oligomers exist in patients with TDP-43-positive frontotemporal lobar dementia (FTLD-TDP)86, 
a form of dementia not associated with tau or Aβ. It should be pointed out again that amyloid 
aggregation results in the formation of a heterogeneous population of oligomers with a diverse 
range of structure and size. Determining the toxicity of specific oligomer assemblies is 
challenging, but it has been postulated that there may be an inverse correlation between oligomer 
size and toxicity81. 
Oligomers have important biochemical properties which that make them more toxic than 
mature amyloid fibrils. Hydrophobic residues of the more inert fibrils are buried within its cross-
β-sheet core; however, these residues are more readily accessible in oligomers and provide an 
interaction surface for other cellular structures and proteins. Oligomers, but not fibers, have been 
shown to interact with and disrupt membranes87. Lastly, oligomers have been shown to seed the 
production of oligomers of other amyloid proteins, initiating a cascade of aberrant assembly of 
toxic proteins within cells88. Indeed, very recent and convincing evidence has indicated that these 
misfolded structures of various proteins might spread from neuron to neuron in a way that 
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resembles the pathological spread of prion proteins89-91.  Precisely how these oligomers are 
causing disease is just now being brought into focus, and a number of well-regulated pathways 
being disrupted by oligomer activity may be pathogenic92,93. In this section, we will discuss new 
research illustrating just how oligomers may promote toxicity within neurons as shown in Figure 
1.1. 
 Astrocytes and microglia regulate neuroinflammation through a host of cytokines, small 
signaling proteins that include chemokines, interferons, interleukins, and tumor necrosis factors 
(TNF). It is well known that a number of neurodegenerative diseases are associated with 
increased inflammation throughout the brain, and increased activity and accumulation of 
microglia and astrocytes precedes deposition of insoluble amyloid, such as Aβ or tau fibrils, in 
AD patients94. Cytokines released by glial cells interact with neuronal receptors to promote 
signaling pathways that have been implicated in several neurodegenerative disorders95-97. 
Chemokines like IL-1, IL-6, and TNFα, released by glial cells are significantly more abundant in 
AD brain tissue than healthy brains, and cytokines can upregulate pathways promoting activation 
of proteins associated with AD, such as protein kinase C or p38 mitogen-activating protein 
kinase98. Prolonged, chronic activation of glial cells associates well with brain atrophy in 
AD99,100.  Protein oligomers may be directly responsible for interacting with glial cells, causing a 
cascade of increasing inflammation and glial activity contributing to neuron loss101.   
It has been proposed by the Kayed group that tau oligomers may induce a positive 
feedback loop by causing neuroinflammation, which in turn induces increased formation of 
oligomeric species. Their studies indicate that tau oligomers co-localize near astrocytes and may 
be responsible for astrocyte activity, leading to increased inflammation101. Additionally, the 
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group found that tau oligomers co-localized with microglia, neural macrophages activated in 
inflammation. In contrast to astrocytes, where oligomers seem to interact near the cell surface, 
microglial cells apparently engulf the oligomers. Phagocytosis and subsequent release through 
exosomes has been reported and may play a role in neural spreading of tau102,103. The authors 
propose that activation of microglia may result from oligomer interaction with the Receptor for 
Advanced Glycation Endproducts (RAGE) receptor, which leads to NFκB activation and 
subsequent upregulation of HMGB1, a pro-inflammatory cytokine. Importantly, RAGE is itself 
upregulated by this process, leading to chronic inflammation. It is also well known that Aβ can 
also induce release of cytokines from astrocytes. A 2011 study by the Noble group showed that 
Aβ treatment of astrocytes increased the amounts of cytokines CINC2α/β, IFN-γ, IL-1β, IL-1ra, 
IL-6, IL-13, IL-17, IP-10 and MIG104. This is important because IL-1β, IL-6, and IP-10 are all 
associated with plaque and tangle pathology in both human AD brains and in mouse models of 
AD. Further studies are needed to identify which receptors oligomers are acting on and to clarify 
the mechanism by which they influence inflammatory pathways. 
 As previously mentioned, proteostasis refers to numerous pathways and cellular 
organelles which function to regulate protein translation, folding, localization and degradation. It 
is well known that proteins abnormally accumulate in numerous neurodegenerative diseases, 
indicating a disruption of degradation and de-aggregation processes required for neuronal 
survival. Oligomers of various proteins associated with neurodegenerative diseases interact with 
these degradation pathways and subsequently inhibit clearance of toxic proteins by the cell. We 
will discuss two major pathways of cellular protein degradation and highlight new areas of 
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research showing how misassembled oligomers may be interacting with and disrupting these 
crucial processes. 
The UPS is a two-step degradation pathway, whereby proteins targeted for degradation 
are first covalently conjugated by to a polyubiquitin chain before being translocated to the 
proteasome. The proteasome is a catalytic complex responsible for the degradation of misfolded 
proteins. The complex consists of a 20S catalytic core along with 19S regulatory subunits on 
either end, which direct misfolded proteins to the catalytic core subunit. Proteolytic activity of 
the proteasome is reduced by proteins central to neurodegenerative diseases, including tau in 
tauopathies, by α-synuclein in PD, and Aβ in AD105.  
Oligomers of diverse neurotoxic proteins interact with and inhibit proteolytic activity of 
the UPS. For example, in an in vitro proteasome activity assay, oligomeric Aβ inhibited 
proteosomal catalytic activity in a dose-dependent manner, whereas the Aβ monomer had no 
effect on proteasome activity105. In a human cell model, Aβ interacted with and sequestered the 
α-subunit of the proteasome into aggregates. Further, in an in vivo mouse model overexpressing 
Aβ, administration of an anti-Aβ antibody results in a reduction of oligomer levels in the brain 
while simultaneously increasing proteasome activity105.  In mice overexpressing a pathologically 
aggregating form of tau containing the P301L mutation, known to cause frontotemporal 
dementia, aggregates of tau directly inhibited the activity of the 26S proteasome106. Finally, α-
synuclein oligomers directly interact and disrupt the activity of the 26S proteasome, indicating a 
common pathology among different oligomer forming proteins107.  
 Another major pathway through which neurons remove or degrade cellular components is 
through macroautophagy, whereby unneeded components are sequestered to a vacuole.  This 
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vacuole subsequently fuses to a lysosome, which contains diverse hydrolytic enzymes capable of 
breaking down proteins and other cellular components. Inhibition of macroautophagy leads to 
accumulation of toxic proteins, such as tau, Aβ, and α-synuclein oligomers108; however, the 
mechanism by which neurotoxic proteins interact and hinder the macroautophagy-driven 
degradation pathway is unclear. Recent work suggests that Aβ has a direct conformation-specific 
role in modifying autophagy and subsequent apoptosis of cells. Beclin-1 is a crucial protein in 
the autophagy pathway, as it initiates the formation of phagosomes through recruitment of other 
proteins. However, if Beclin-1 interacts with bcl-2, it prevents autophagosome formation and 
leads to apoptosis, or neuronal death109.  Interestingly, while monomers of Aβ inhibit this 
interaction, Aβ oligomers actually enhance the formation of Beclin-1:bcl-2 complexes and cause 
neuronal death110. Because oligomers of diverse toxic proteins seem to have similar effects on 
cellular pathways and organelles, amyloidogenic proteins other than Aβ may also directly impair 
autophagy. 
Neuronal damage precedes fibrillary tau aggregates, suggesting that prefibrillar oligomers 
may be neurotoxic. Loss of neurons ultimately causes cognitive and motor impairments in 
animal models and in human neurodegenerative diseases. However, oligomeric forms of 
amyloidogenic proteins cause disruptions in synaptic activity and plasticity well before cellular 
degeneration. Synaptic dysfunction rather than neuron loss may be the cause of motor 
impairment and memory loss early in neurodegenerative disease progression111,112. Aβ oligomers 
have been shown to inhibit hippocampal long term potentiation and enhance long term 
depression well before cellular degeneration113,114, which suggests a potential means of reversal 
of neurodegenerative symptoms if diagnosed early115,116.  Soluble oligomeric amyloids associate 
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with synaptic proteins, resulting in impairments in synaptic function. Aβ oligomers associate 
with post-synaptic density complexes containing N-methyl-D-aspartate (NMDA) receptors and 
cause impairment of NMDA receptor-mediated calcium entry and decreased dendritic spine 
density117,118. Aβ oligomers have been demonstrated to cause impaired synaptic trafficking of 
ionotropic and metabotropic glutamate receptors45,112 and to induce abnormal glutamate release 
from hippocampal neurons, which may contribute to excitotoxic signaling119. Soluble amyloid 
oligomers also induce dysregulation of calcium sequestration and signaling through a mechanism 
of increased membrane permeability independent of Ca2+ channel activation120. Aβ oligomers 
and tau oligomers have also been shown to disrupt axonal transport mechanisms121,122 that are 
critical for the maintenance of healthy synapses. Impaired neuronal signaling resulting from 
oligomeric amyloid proteins should be reversible prior to neuron loss, providing hope that 
eventually an appropriate therapeutic combined with early detection could one day facilitate 
reversal of disease progression.  
1.3.5 How can protein misfolding be targeted?  
Detection and diagnosis of neurodegenerative diseases continue to move away from post-
mortem analysis of protein aggregates in the brain towards non-invasive early detection.  Many 
methods from genetic testing123, molecular and functional imaging124, and blood and 
cerebrospinal fluid (CSF) biomarkers125, to retinal scanning126,127 and exhaled volatile biomarker 
fingerprints128 involve non-invasive tests to seek correlations between specific biomarkers and 
disease. Here we focus on the non-invasive detection of misfolded proteins or interacting 
chaperones rather than numerous other potential correlative biomarkers.  
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 In AD, the intracellular accumulation of misfolded species of amyloidogenic proteins 
such as Aβ and tau is also accompanied by the secretion of these proteins from neurons.  
Remarkably, these proteins can be detected in the CSF and have even been detected in blood. 
Multiple studies have evaluated the detection of amyloidogenic proteins in the blood or CSF123.  
The focus of peripheral Aβ detection has been on the ratio of Aβ40/Aβ42129, and, more recently, 
on smaller Aβ fragments, such as Aβ17130.  Similarly, CSF and blood tau detection efforts have 
included both total and phosphorylated tau131.  The extracellular chaperone clusterin has also 
emerged as a potential biomarker for AD123,132. Similarly, in Parkinson’s disease (PD), changes 
in the levels of α-synuclein (an intrinsically disordered protein found in pathological 
intraneuronal hallmarks of PD, Lewy bodies and Lewy neurites) in various biofluids, such as 
cerebrospinal fluid (CSF), plasma, blood, and saliva, are used as disease-specific and early-stage 
biomarkers133. Interestingly, the best fitting predictive models for discriminating PD patients 
from controls can be built using a combination of multiple CSF α-synuclein species, such as 
total-, oligomeric- and phosphorylated α-synuclein, with classical AD biomarkers, such as 
phosphorylated tau134. 
Nevertheless, consistency and reproducibility of using amyloidogenic proteins as blood 
biomarkers can be challenging.  For example, variability in blood-brain barrier integrity will 
have a profound effect on blood detection of selected biomarkers of brain origin, leading to poor 
correlation with stage of disease.  Additionally, quantitation of proteins with disordered regions 
possessing high binding potential and/or a propensity to aggregate can be challenging, as the 
target protein may stick to other proteins on vascular and blood cells as wells as to undergo self-
aggregation that would mask epitopes used for detection.  
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Molecular imaging of amyloidogenic protein accumulation has become a promising 
noninvasive detection method for correlation with neurodegenerative disease progression. Three 
PET imaging agents targeting Aβ accumulation have been approved by the FDA for the 
estimation of Aβ neuritic plaque density. However, some patients present as Aβ positive with no 
dementia symptoms, making the hope of a simple imaging diagnosis more complicated.  
Therefore, initial approval was designed to rule out AD in Aβ-negative patients with dementia135 
, but longitudinal studies of cognitively normal patients with significant Aβ burden may help to 
determine whether progression to AD is inevitable. A large multicenter clinical study in the 
United States, the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) study, aims to 
evaluate how amyloid imaging affects diagnosis, patient management, and outcomes. Several 
tau-targeted PET imaging agents are emerging and entering clinical trials as well as becoming 
incorporated into clinical trials evaluating potential therapeutics136. The pattern of tau tracer 
retention appears to correlate with disease progression and with the Braak staging pattern of tau 
deposition in autopsy studies137. Many PET imaging strategies for Parkinson’s Disease focus on 
uptake of agents through monoamine transporters138, however there is an intense focus on the 
development of agents targeting aggregates of α-synuclein139-141. 
Overall, treatment options for neurodegenerative diseases have been very disappointing, 
with the majority of them failing to produce any significant benefits, while others end up doing 
more harm than good. FDA-approved therapeutic strategies are limited to pharmacological 
modulation of neurotransmission to counteract a loss in synaptic connections and/or 
neurons142,143. Future strategies for the development of therapeutics for neurodegenerative 
protein misfolding disorders are varied and include stem cell replacement, immunotherapy, gene 
 
 
 
19 
 
 
therapy, targeting modulators of protein aggregation, and degradation and targeting of misfolded 
proteins themselves. Here we will highlight a few therapeutic strategies that are focused on 
modifying misfolded or aggregated protein. 
Active immunization research through vaccination with amyloidogenic protein epitopes 
has shown some promise in certain animal models of neurodegeneration and in early clinical 
trials. Vaccination against N-terminal peptides of Aβ144,145 or peptides and phosphopeptides 
representing tau protein146-148 have been evaluated. However, active vaccination carries the risk 
of inducing an excessive immune response in the brain, evidenced by occurrences of 
meningoencephalitis in clinical trials. Mimetics of protein epitopes are also being used for 
vaccination strategies designed to induce a therapeutic immune response to Aβ149 and α-
synuclein150 in hopes of reducing the risk of autoimmunity associated with native antigens. 
Additionally, adjuvant-free immunotherapies, including passive and DNA immunization, may 
avoid undesirable immune reactions. 
Several antibodies developed against certain species of amyloidogenic aggregates have 
been extensively tested clinically as passive immunotherapy. For example, aducanumab is a 
human monoclonal antibody that selectively targets aggregated Aβ. Tested in patients with mild 
AD in a small, Phase I trial, Aducanumab showed a reduction of Aβ in a dose- and time-
dependent manner, as well as a clinical improvement as measured by the Clinical Dementia 
Rating – Sum of Boxes and Mini Mental State. Aducanumab is currently being tested in a phase 
III clinical trial on patients with early AD151 (NCT02477800). Crenezumab, an antibody 
targeting multiple forms of Aβ, and gantenerumab, an antibody that specifically recognizes Aβ 
fibrils, are both currently being investigated in phase III clinical trials for their efficacy as AD 
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treatments (NCT02565511, NCT02670083, NCT02051608, NCT01224106). Solanezumab was 
developed as a humanized monoclonal IgG1 antibody recognizing soluble Aβ, in the hopes of 
targeting the smaller, more toxic Aβ species. Although solanezumab has been investigated in 
several phase III clinical trials without producing clinically significant differences on primary 
outcomes (NCT00904683), it is still being tested as a combination therapy with other potential 
AD treatments (NCT01760005).  Less specific to Aβ, a phase III clinical trial examining the role 
of intravenous immune globulin (IGIV) as an add-on treatment for AD, a part of the 
Gammaglobulin Alzheimer’s Partnership (GAP) study, failed to meet the primary outcome 
measures (NCT00818662). 
Similarly, antibodies specific for particular species of tau are in clinical development for 
passive immunotherapy152 (NCT02820896, NCT02880956, NCT02460094). Most of these 
antibodies recognize tau phosphorylated at specific sites152, while others target particular peptide 
sequences153 or specific conformations154. Certain antibodies in clinical and preclinical 
development specifically target only prefibrillar oligomeric forms of tau155-157. 
The development of antibodies against α-synuclein are progressing for treatment of PD 
and other synucleinopathies by reducing aggregation and toxicity144,158. PRX002, a monoclonal 
antibody against α-synuclein is now being investigated for its role in reducing α-synuclein levels 
in patients with PD (NCT02157714). 
The delivery of therapeutic genes into the cells of patients with disease, usually using 
viral vectors, is yet another therapeutic strategy. One gene therapy strategy involves the 
expression of genes encoding single-chain antibody fragments (intrabodies) into cells159. In this 
way, some of the same antibodies developed for passive immunotherapy could be reengineered 
 
 
 
21 
 
 
for intracellular expression. Intrabodies have been developed to target Aβ160, α-synuclein161, and 
regions adjacent to the polyQ tract in huntingtin162-164. Similarly, an engineered protein not based 
on an antibody scaffold that also binds to and modulates amyloid aggregation, Aβ-binding 
Affibody ZAβ3, represents another potential gene therapy strategy165. Gene therapy may also be 
used to deliver genome-editing technologies, such as CRISPR and zinc-finger nucleases. This 
has particular promise for a purely genetic disease like Huntington’s disease, where silencing or 
editing out the expanded CAG repeats at the DNA level could halt production of the 
aggregation-prone protein166,167.  Additionally, gene therapy delivery may allow the expression 
of proteins that have a propensity to reduce the aggregation of amyloidogenic protein.  Certain 
chaperone proteins interfere with amyloid aggregation, including αB-crystallin, clusterin, Hsp27 
and Hsp70168-170. Likewise, a number of non-chaperone proteins have been found to reduce 
amyloid aggregation, including catalase, pyruvate kinase, and the prolyl isomerase PIN1171,172. 
While natural proteins that reduce amyloid aggregation may be promising targets for gene 
therapy, other endogenous proteins that exacerbate amyloid aggregation may be potential 
therapeutic targets for inhibition.   
 Chaperones and enzymes that associate with misfolding proteins, like tau and Aβ, are 
potential therapeutic targets in neurodegenerative disease. Hsp90 is a major chaperone which 
helps fold, refold, and stabilize various proteins. Though aberrantly misfolded tau is normally 
degraded in the proteasome, Hsp90 in concert with co-chaperones stabilize tau, preventing 
normal degradation and thereby leading to accumulation. Inhibition of Hsp90, in vitro, allows for 
uninterrupted tau degradation173. Furthermore, Hsp90 increases the formation of β-sheet-rich tau 
fibrils and in complex with the co-chaperone FKBP51, produces neurotoxic oligomeric tau174. 
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Because Hsp90 helps maintain levels of kinases and other proteins required for cancer cell 
survival, it has become a promising target in the fight against cancer, and well-characterized 
drugs developed for Hsp90 inhibition may also have implications in neurodegenerative disease. 
Conversely, because of the importance of Hsp90 in proteostasis and the extensive list of Hsp90-
interacting proteins175, targeting of Hsp90 co-chaperones, like FKBP51, may prove to be an 
alternative therapeutic approach with less toxicity due to a smaller subset of chaperone client 
proteins. 
Beta-secretase (BACE-1) is the enzyme that cleaves amyloid precursor protein (APP) 
into the C99 fragment, which can then be cleaved by gamma-secretase into Aβ fragments. 
Reducing the amount of Aβ fragments using a BACE inhibitor is thought to be a good 
therapeutic strategy for AD. Several BACE inhibitors are currently being tested in phase III 
clinical trials. For example, small molecules AZD3293, CNP520, and JNJ-54861911 are all 
BACE-1 inhibitors being investigated for their efficacy at various stages of AD (NCT02245737, 
NCT02783573, NCT02565511, NCT02569398). Verubecestat is a small-molecule inhibitor of 
BACE-1 and BACE-2 and is currently being used in a phase III clinical trial to examine its 
efficacy in mild to moderate cases of AD176 (NCT01739348, NCT01953601). 
There are several other potential therapeutics being tested for the treatment of AD, such 
as an inhibitor of Aβ polymerization and inflammation (ALZT-OP1) and an inhibitor of tau 
aggregation (TRx0237). ALZT-OP1 is a combination therapy of two FDA-approved drugs: 
cromolyn and ibuprofen. Both drugs have anti-inflammatory mechanisms: cromolyn stabilizes 
mast cells and suppresses cytokine release, whereas ibuprofen is a widely used non-steroidal 
anti-inflammatory drug. Cromolyn has also been shown to inhibit aggregation of Aβ monomers 
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in vitro, and decrease soluble Aβ levels in vivo177. ALZT-OP1 is currently being investigated in a 
phase III trial in patients with early AD. TRx0237 is a reduced form of Methylene Blue 
(methylthioninium chloride, MTC) that has been designed to stabilize this dye to improve its 
absorption, bioavailability, and tolerability178. TRx0237 is thought to both prevent tau 
aggregation and dissolve existing aggregates178. Several phase III trials have examined the 
effects of TRx0237 on cognition (NCT01626378, NCT01689246, and NCT01689233). Two of 
the clinical trials failed to meet their primary outcomes, and the results of another has are not yet 
to published its results. Additional phase III therapeutics are summarized in Table 1.2. 
1.4 Conclusions 
Maintenance of cellular proteostasis is essential for cellular health and is regulated by a 
variety of proteins involved in proper protein folding, trafficking and degradation pathways.  
Thousands of different proteins, each with multiple isoforms and PTMs, are continuously 
translated, properly folded, associated with binding partners, shuttled to required subcellular 
locations and degraded as needed.  A handful of proteins develop a propensity to misfold due to 
an inherently disordered structure, mutation or PTM. In the brain, these proteins cause the 
appearance of large fibrillar aggregates and neurodegeneration, leading to cognitive and motor 
deficits, such as dementia and dystonia. However, smaller prefibrillar oligomeric aggregates also 
continue to accumulate throughout disease progression.  These toxic oligomers can have 
deleterious effects on neuronal function, including synaptic dysregulation, neuroinflammation, 
and the disruption of protein degradation via the UPS and autophagy.  Dysregulation of neuronal 
function may be reflected by cognitive or motor deficits in an early phase of disease progression, 
prior to significant neuron loss. This could represent a window of therapeutic opportunity that 
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could be enabled by early diagnosis and oligomer-modifying drugs.  Ongoing research towards 
an understanding of the structural determinants of toxic oligomers and the cellular pathways that 
modulate their formation will facilitate the development of new diagnostic and therapeutic 
strategies as well as the refinement of strategies currently in clinical trials. 
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Table 1.1 Neurodegenerative disorders and associated misfolded proteins 
Disease Misfolding or Aggregating Protein Manifestation 
Alzheimer’s Disease Amyloid-β 
Tau 
Plaques 
Neurofibrillary tangles 
Amyotrophic Lateral Sclerosis SOD-1 
TDP-43 
FUS 
Dipeptide repeat proteins 
Inclusion bodies 
Corticobasal Degeneration Tau Fine filamentous 
inclusions 
glial plaques 
Frontotemporal Dementia Tau 
TDP-43 
FUS 
Pick bodies 
Inclusion bodies 
Huntington’s Disease Huntingtin Inclusion bodies 
Lewy Body Dementia α-synuclein 
May co-occur with (Aβ and/or tau) 
Lewy Bodies 
Progressive Supranuclear Palsy Tau 
 
May co-occur with α-synuclein 
Neurofibrillary tangles 
Tau tufted astrocytes 
Lewy bodies 
Parkinson’s Disease α-synuclein Lewy Bodies 
Familial amyloid 
polyneuropathies 
transthyretin Amyloid fibrils 
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Figure 1.1 Toxic gain of function. Some proteins can form oligomers that have deleterious 
effects on neurons and cause neurodegenerative disorders. Certain events like post-translational 
modification or transient unfolding of proteins can lead to self-association and soluble oligomer 
formation. It has been shown that these oligomers can seed the formation of long amyloid fibers. 
Additionally, increasing evidence supports that misfolded proteins involved in 
neurodegeneration, like such as tau, spread throughout the brain and propagate in a prion-like 
manner. Oligomers are known to directly act with key regulatory proteins throughout the brain 
and have been shown to increase neuroinflammation and disrupt degradation pathways, 
including the ubiquitin-proteasome pathway and autophagy. Lastly, oligomers can interact at the 
synapse to impede neurotransmission. 
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Table 1.2 Experimental Therapeutics Targeting Misfolded Proteins for Neurodegenerative 
Diseases 
 
Therapeutic target Examples (drug – disease) Clinical phase 
Active immunotherapy AADvac1 – AD  
ACI-35 – AD  
CAD106 – AD 
AFFITOPE PD01A – PD 
Phase II 
Phase I 
Phase II 
Phase I 
Passive immunotherapy Aducanumab – AD  
Crenezumab – AD  
Gantenerumab – AD  
Immune globulin – AD  
Solanezumab – AD 
BMS-986168 – Tauopathies  
C2N-8E12 – Tauopathies  
PRX002 – PD   
Phase III 
Phase III 
Phase III 
Phase III 
Phase III 
Phase I 
Phase I 
Phase I 
Gene therapies  Intrabodies – AD, PD, HD 
CRISPR – HD  
 
Aggregation modulating proteins AZD3293 – AD 
CNP520 – AD   
JNJ-54861911 – AD  
Verubecestat – AD  
Hsp90 inhibitors – AD  
Phase III 
Phase III 
Phase III 
Phase III 
Targeting misfolded proteins ALZT-OP1 – AD  
TRx0237 – AD  
Phase III 
Phase III 
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CHAPTER TWO1: 
 
CYCLOPHILIN 40 UNRAVELS NEUROTOXIC AMYLOIDS 
 
2.1 Abstract 
The accumulation of amyloidogenic proteins is a pathological hallmark of 
neurodegenerative disorders. The aberrant accumulation of the microtubule associating protein 
tau (MAPT, tau) into toxic oligomers and amyloid deposits is a primary pathology in 
tauopathies, the most common of which is Alzheimer’s disease (AD). Intrinsically disordered 
proteins, like tau, are enriched with proline residues which regulate both secondary structure and 
aggregation propensity. The orientation of proline residues is regulated by cis/trans peptidyl-
prolyl isomerases (PPIases). Here we show that cyclophilin 40 (CyP40), a PPIase, dissolves tau 
amyloids in vitro. Additionally, CyP40 ameliorated silver-positive and oligomeric tau species in 
a mouse model of tau accumulation, preserving neuronal health and cognition. NMR revealed 
that CyP40 interacts with tau at sites rich in proline residues. CyP40 was also able to interact 
with and disaggregate other aggregating proteins which contain prolines. Moreover, CyP40 
lacking PPIase activity prevented its capacity for disaggregation in vitro. Finally, we describe a 
unique structural property of CyP40 which may permit disaggregation to occur in an energy-
independent manner. This study identifies a novel human protein disaggregase and, for the first 
time, demonstrates the capacity of dissolving intracellular amyloids.  
____________________ 
1Portions of this work were previously published (Baker, J.D. et al., 2017) and are used with permission of 
the publisher. 
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2.2 Introduction 
Most mammalian proteins have intrinsic sequences that promote amyloid fibril formation 
179. This is believed to be a natural process to prevent the formation of more toxic amorphous, 
intermediate structures 179,180. However, in some cases such as neurodegenerative disease, 
aberrant amyloid formation promotes proteotoxicity 181. Recent evidence suggests endogenous 
protein complexes have the ability to dissolve these potentially toxic amyloidogenic structures 20. 
This work has not only shed light on novel cellular pathways of disaggregation, but also suggests 
that these proteins could be exploited to mitigate disease pathogenesis. For example, the yeast 
disaggregase, Heat shock protein (Hsp)104, utilizes ATP hydrolysis to disaggregate a variety of 
human proteins in a yeast model 182,183. More recently, the human Hsp70/DnaJ/Hsp110 complex 
was shown to facilitate the disaggregation of amyloid substrates in vitro in an ATP-dependent 
manner 184. But the dynamic and ubiquitous nature of aggregation and disaggregation in cells 
suggests that a more energy-efficient process might exist, one not dependent on ATP. However, 
a mammalian ATP-independent amyloid unraveling enzyme has yet to be identified.  
For many proteins, amyloidogenesis is significantly affected by structurally rigid proline 
residues 185,186, which unlike other amino acids have a more energetically favorable cis-
conformation 187. This unique nature of proline residues enables major changes in protein tertiary 
structure through cis-trans isomerization 188. In neurodegenerative disorders, such as 
Alzheimer’s disease (AD) and Parkinson’s disease (PD), amyloidogenic proteins (Aß and tau in 
AD and α-synuclein in PD) form stacked ß-sheets 187-189 containing ß-turns 190. Because proline 
residues, which are enriched in tau and other intrinsically disordered proteins, are frequently 
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found in ß-turns191191190, we hypothesized that enzymes capable of twisting these residues could 
unravel amyloids.  
The family of cis/trans peptidyl prolyl isomerases (PPIases) is diverse 192, and, perhaps 
most importantly, does not require the use of ATP to isomerize proline residues 193. Previous 
work, by our group as well as others, demonstrated PPIases regulate tau aggregation 194-196. 
Despite the fact that ß-turns often contain prolines, amyloid disaggregation via PPIases has never 
been demonstrated. Thus, we speculated that discrete PPIases may disaggregate amyloids in a 
proline-dependent manner. Here, we describe the isomerase-dependent effects of human 
cyclophilin 40 (CyP40) in amyloid disaggregation. CyP40 is a member of the cyclophilin family, 
which along with FK-506 binding proteins (FKBPs) and parvulins, comprise a group of proteins 
known as immunophilins 197. Cyclophilins (CyPs) are defined by their ability to bind 
Cyclosporin A (CsA). Upon binding CyPs suppress the immune system through deactivation of 
calcineurin, a regulator of inflammatory inducing transcription factors 198. CyPs also play a key 
role in the folding of nascent proteins by catalyzing the cis to trans conformation of proline 
residues, a rate limiting step in proper folding 199,200. Recent work has shown that the isomerase 
activity of CyP40 is regulated through its interaction with Hsp90 and when CyP40 is bound to 
Hsp90, isomerase activity is reduced. Cellular stress can release CyP40 from Hsp90 
subsequently increasing CyP40 isomerase and chaperone activity 201.  
In this study, we identified a novel disaggregation mechanism. For the first time, we 
showed that a PPIase is capable of disaggregating amyloids. We demonstrated that CyP40 
exhibits disaggregation activity dependent on interactions with proline residues and independent 
of co-factors such as ATP.  Further, two conformational states of CyP40, found in the Protein 
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Data Bank, provided evidence for a potential mechanism by which amyloid binding and 
subsequent conformational changes in CyP40 may drive ATP-independent disaggregation 
activity. Transduction of CyP40 in a tauopathic brain reduced tau oligomers and tangles, yielded 
significant improvements in neuronal health, and preserved cognitive function. Together, these 
data implicate CyP40 as a potential therapeutic intervention for tauopathies and other 
amyloidogenic disorders. 
2.3 Materials and Methods 
2.3.1 Study approval 
All applicable international, national, and/or institutional guidelines for the care and use 
of animals were followed. All animal handling and procedures were carried out in accordance 
with the University of South Florida’s Institutional Animal Care and Use Committee (IACUC) in 
accordance with the Association for Assessment and Accreditation of Laboratory Animal Care 
International (AAALAC) regulations. 
2.3.2 Protein Purification 
Recombinant human tau P301L, CyP40, CyP40 H141E, FKBP51, and FKBP52 were 
cloned into bacterial expression vectors, protein was expressed in E.coli BL21 cells, purified and 
dialyzed. Proteins were estimated to be >95% pure by coomassie staining. The details are given 
in the Supplemental Experimental Procedures. Amyloid Beta protein fragment 42 was purchased 
from Sigma Aldrich (107761-42-2), and mature α-synuclein fibrils were generated according to 
the established protocol by shaking the α-synuclein solution, at a concentration of 0.3 mg/ml 
(20.8 μM), in 10 mM HEPES buffer (pH 7.5), 100 mM NaCl.   
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2.3.3 Fibril formation 
50 µM recombinant human tau P301L was incubated in the presence of 12.5 µM low 
molecular weight heparin at 37°C in 100 mM Sodium Acetate pH 7.0 buffer without agitation 
for 7 days. Aβ42 fibrils were formed by suspending the lyophilized protein in minimal 60 mM 
NaOH and then diluting to 50 µM in PBS buffer. The solution was then shaken at 700 rpm at 
37°C for 5 days. Thioflavin T fluorescence was recorded throughout fibrillation in order to 
confirm a plateau of fluorescence. 
2.3.4 Thioflavin T Fluorescence Assay 
7.5 µM pre-fibrillized tau was incubated with 7.5 µM CyP40 (wt or mut where indicated) 
protein (in 100 µM Sodium Acetate pH 7.0 buffer for tau or PBS for α-synuclein and Aβ42) in 
100 µL volumes in 96-well black clear-bottom plate (Fisher #07-200-525). At set time points (0, 
1, 3 hrs), 7.5 µM Thioflavin T (final concentration) was added and fluorescence read at 440 nm 
excitation and 482 nm emission in a BioTek Synergy H1 plate reader. All conditions were 
performed in at least duplicate. 
2.3.5 Transmission Electron Microscopy 
10 µL of protein samples were adsorbed onto square mesh copper grids (EMS300-Cu) for 
30 seconds, washed twice with 10 µL of deionized water and excess water removed. Samples 
were negatively stained with 4% uranyl acetate for 30 seconds and dried overnight. Grids were 
viewed using a JEOL 1400 Digital Transmission Electron Microscope and images were captured 
with a Gatan Orius wide-field camera. Fields shown are representative. 
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2.3.6 Nanoparticle tracking analysis 
Samples were diluted 10,000 fold into 1 mL of 0.02 µm filtered deionized water. 
Approximately 300 µL of sample was loaded onto the Malvern Nanosight LM10 equipped with 
a 633 nm red laser. Protein particle data was captured with a Marlin CCD camera in duplicate. 
Graphs were generated by Nanosight software. 
2.3.7 Circular dichroism (CD) spectroscopy 
 Far-UV CD measurements were taken using a JASCO J-815 spectropolarimeter. wt 
CyP40 and mut CyP40 were dialyzed into 10 mM sodium phosphate buffer, pH 7.5 and readings 
were taken at 25°C. Each spectrum is an average of 3 scans from 190-260 nm at 50 nm/min. 
Buffer spectral curves were subtracted for each protein. 
2.3.8 Nuclear magnetic resonance spectroscopy 
15N-labeled human tau and α-synuclein proteins were expressed and purified as described 
previously 202,203. NMR samples contained 15 µM 15N single-labeled α-syn protein in 50 mM 
HEPES buffer (pH 6.8), 100mM NaCl, 0.02% NaN3 and 10% (v/v) D2O or 20 µM 15N single-
labeled tau protein in 50 mM phosphate buffer (pH 6.8), 0.02% NaN3 and 10% (v/v) D2O. 
Unlabeled CyP40 and FKBP51 samples were dialyzed in the same buffers. NMR experiments of 
α-synuclein and tau were recorded at 15°C and 5°C, respectively on 600, 700, 800 and 900 MHz 
spectrometers (Bruker) equipped with cryogenic or room-temperature probes. Final 
concentrations of CyP40 and FKBP51 were 200 µM while tau was 20 µM. Two-dimensional 
1H–15N heteronuclear single-quantum coherence (HSQC) spectra were acquired in the case of α-
synuclein using 256 complex points in the indirect dimension and 64 increments with spectral 
widths of 8417.5 and 1776.1 Hz in the 1H and 15N dimensions or with 512 complex points in the 
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indirect dimension and 40 scans with spectral widths of 8417.5 and 1705.1 Hz in the case of tau. 
Spectra were processed with NMRPipe 204 and analyzed using Sparky (T. D. Goddard and D. G. 
Kneller, SPARKY 3, University of California San Francisco). NMR intensity ratio plots were 
reported with a 3-residues averaging window.  
2.3.9 iHEKP301L and sarkosyl-insoluble analysis 
iHEK cells expressing tau P301L 205 for 9 days were transfected PCMV6-CyP40 (wild-
type and H141E mutants) plasmids using Lipofectamine 2000 (Invitrogen). 48 h after 
transfection, the sarkosyl-insoluble fraction of tau was prepared as previously described 206. The 
details are given in the Supplemental Experimental Procedures. 
2.3.10 Mouse studies and tissue processing 
Transgenic mice overexpressing human tau P301L under a CaMKII promoter were 
injected with AAV9 vector at 6-months old (N = 8 [4 male, 4 female] for CyP40, N = 8 [4 male, 
4 female] for GFP), and brain was harvested at 8-months old after perfusion using 0.9% saline as 
previously described. Hippocampi was dissection from the right hemisphere and was snap frozen 
for biochemical processing.  The left half of the brains were fixed in 4% paraformaldehyde 
overnight. Sucrose gradients up to 30% were used and tissue was sectioned with a sliding 
microtome to 25 µm thickness.  rTg4510 along with non-transgenic control mice were injected 
with AAV9 at 3-months of age (N = 20 [10 non-transgenic; 5 male, 5 female], [10 transgenic; 5 
male, 5 female] for Cyp40, N = 18 [9 non-transgenic; 5 male, 4 female], [9 transgenic; 5 male, 4 
female] for GFP).  These mice were used for behavioral testing at 5-months. 
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2.3.11 Stereology 
              Neurons were stained with anti-NeuN and cresyl violet, and those positive for both were 
counted in the CA1 of the hippocampus. A computerized stereological system, connected to a 
Leica DM4000B microscope with a Prior motorized stage, was used to outline the area using 
distinct landmarks in the brain at 4x magnification 205,207. Neurons were counted in this region by 
using randomly designated areas in the computer-generated grid using a 100x oil immersion lens. 
Neurons were counted when they were located within the three-dimensional dissectors or 
touching the inclusion lines, and the top and bottom 1 µm of tissue were excluded.  
2.3.12 Viral injection 
Using stereotaxic equipment, mice were injected bilaterally into the hippocampus at X= 
±3.6 Y= -3.5 Z= +2.68.  Each injection delivered 2 μL of 1 x 1012 particles/mL of AAV9-GFP  
or AAV9-CyP40.    
2.3.13 Immunohistochemistry and immunofluorescence 
Tissue staining, imaging and quantification are described in detail in the Supplemental 
Experimental Procedures. 
2.3.14 Radial-arm water maze 
A circular black tank with a six arm metal insert was filled with water and a platform was 
submerged 1 cm below the surface of the water at the end of a designated goal arm. Animals 
were permitted 60 seconds to locate the platform, during which time an observer blind to 
treatment manually scored the number of errors. An error was defined as an entry into an 
incorrect arm or the absence of an arm choice within 15 seconds. Mice were trained over 2 days 
with 15 trials per day, which were divided into 5 sessions of 3 trials each. 
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2.3.15 Fear conditioning 
Two mild foot shocks (0.5 milliamps) were paired with an auditory conditioned stimulus 
(CS, white noise, 70 decibels) within a novel environment. The CS was given for 30 s before 
each foot shock (2 s). Twenty-four hours later, mice were placed into a novel context for 3 min 
without CS and then exposed to the CS for 3 min (cued). 
2.3.16 Intrinsic disorder analysis 
 The intrinsic disorder predisposition of human CyP40 (UniProt ID: Q08752) was 
evaluated by four algorithms from the PONDR family, PONDR® FIT 208, PONDR® VLXT 209, 
PONDR® VSL2 210, and PONDR® VL3 211, as well as by the IUPred web server with its two 
versions for predicting long and short disordered regions 212. The consensus disorder propensity 
of human CyP40 was evaluated by averaging disorder profiles of individual predictors. 
2.3.17 Statistical Analysis 
Analyses were performed using GraphPad Prism version 5.02. Group differences were 
analyzed with Student’s t-test, one-way or two-way ANOVA as indicated in figure legends. P-
values less than 0.05, 0.01, or 0.001 are marked by one, two or three asterisks (*), respectively. 
Error bars represent standard error of the mean (SEM). Data were examined for normal 
distribution and variance to determine if any datasets needed further analysis. 
 Sample sizes were not predetermined by statistical methods. Sample size estimates for 
animal studies were chosen based on previous experience with the rTg4510 mouse model. Data 
met assumptions for each test as analyzed by Shapiro-Wilk normality tests. Variation within 
groups was not significantly different as analyzed by F-test of equality of variances. Animals 
 
 
 
37 
 
 
were randomized into experimental groups by an investigator blinded to genotype and treatment. 
Researchers were blinded for tissue analysis, stereology, and mouse behavior 
2.3.18 Recombinant Protein Purification 
Recombinant human tau P301L, CyP40, CyP40 H141E, FKBP51, and FKBP52 were 
cloned into PET28A plasmids with a TEV protease sequence, and then transformed into 
competent E.coli BL21 cells and plated on kanamycin-agar plates and incubated at 37°C 
overnight (~16 hrs). A single colony was used to inoculate a 10 mL starter culture of LB broth 
supplemented with kanamycin. After 8-12 hrs, starter cultures were used to inoculate 1 L of LB-
kanamycin broth and cultures were grown to an OD600 of 0.8 (~3 hrs). At this point, cultures 
were induced with 1 mM (final concentration) IPTG and grown a further 3 hrs. Pellets were spun 
down at 3500 x g for 30 min and supernatant was discarded by aspiration. Pellets were then 
resuspended in Nickel chromatography running buffer (20 mM Tris-HCl pH 8.0, 500 mM NaCl, 
10 mM Imidazole) and frozen for up to 3 months at -80°C. 
Pellets were then thawed on ice and subsequently lysed by sonication and spun at 50,000 
x g for 1 hr. After filtration of the supernatant with a 0.02 µm filter, a standard gravity nickel 
column using Ni-NTA resin (Fisher #PI88222) was performed. TEV protease was then added to 
the elution fraction, placed into a 3,000 MW cutoff dialysis bag and into TEV buffer overnight at 
4°C. The solution was then dialyzed back into nickel chromatography running buffer and a 2nd 
nickel purification column was ran. We then performed size exclusion chromatography using a 
HiLoad 16/600 Superdex 200pg column and fractions were pooled and concentrated. Proteins 
were then dialyzed into appropriate buffer (PBS or Sodium Acetate). Proteins were estimated to 
be >95% pure by coomassie staining. 
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2.3.19 Chymotrypsin-coupled assay 
PPIase activity was measured by a chymotrypsin-coupled assay using a synthetic peptide 
succinyl-Ala-Ala-Pro-Phe-p-nitroanilide (Sigma) as previously described 213 with some 
modifications. Briefly, the reactions were set up in precooled 1 ml reaction buffer (50 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 10 mM CaCl2) by adding 5 µl 1 mM peptide, 1 µl chymotrypsin (1 
mg/ml, Sigma), and 0.5 µM purified protein. The absorbance was measured every 20 seconds for 
10 min at 410 nm in a Genesys 10S UV-Vis spectrophotometer (Thermo) at 4°C.  
2.3.20 iHEKP301L and sarkosyl-insoluble analysis 
The tetracycline-inducible HEK293 cell line (iHEK) was generated by the insertion of 
human tau P301L 4R0N DNA into a pCDNA 4/TO plasmid vector (Invitrogen). The tau/TO 
plasmid construct was transfected into the T-REx™ HEK cell line (Invitrogen) which stably 
expresses the tetracycline repressor protein. After zeocin selection (200 µg/ml), the colonies 
were picked up and the expression of Tau was detected by Western blot with and without 
tetracycline (1 µg/ml). Cell lines were found to be free of mycoplasma contamination. 
To investigate the effect of CyP40 on the level of aggregated, insoluble tau, tau 
expression was induced for 9 days and then transfected with PCMV6-CyP40 (wild-type and 
H141E mutants) plasmids using Lipofectamine 2000 (Invitrogen) following the manufacturer’s 
instructions. 48 h after transfection, the sarkosyl-insoluble fraction of Tau was prepared as 
previously described 206. 
2.3.21 Immunohistochemistry and immunofluorescence 
Tissue was stained free floating. Tissue sections were incubated in PBS supplemented 
with 10% MeOH and 3% H2O2 to block endogenous peroxidases.  Following PBS washes, tissue 
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was permeabilized by 0.2% Triton-X-100 with 1.83% lysine and 4% serum in PBS for 30 min.  
Tissue was then incubated at room temperature overnight in primary antibody.  The following 
primary antibodies were used: anti-CyP40 (1:2000, Pierce PA3-023), T22 (1:700, Dr. Rakez 
Kayed), and anti-H150 tau (1:30000, Santa Cruz SC-5587).  Following three PBS washes, 
biotinylated goat anti-rabbit (Southern Biotech) secondary (1:10000) was added for 2 hrs.  Prior 
to peroxidase development, an ABC kit (Vectastain) was used to increase visibility.  Following 
PBS washes, tissue was incubated with 0.05% diaminobenzidine plus 0.5% nickel and developed 
with 0.03% H2O2.  Tissue sections were then mounted and allowed to dry overnight before 
dehydration in alcohol gradients.  Slides were cleared by Histoclear then coverslipped with DPX 
(distyrene, plasticizer, and xylene) mountant as a synthetic resin mounting media.  
Sections stained for stereology were blocked and permeabilized as described above and 
incubated overnight with biotinylated NeuN (1:3000, EMD Millipore MAB377B) at room 
temperature.  Following PBS washes, ABC conjugation, and peroxidase development tissue was 
mounted on glass slides and dried overnight.  These sections were then counter-stained with 
cresyl violet (nissl) by incubating with 0.05% cresyl violet briefly and then quickly destaining 
with 0.3% acetic acid in water prior to dehydration. 
For Gallyas silver staining, tissue slices were mounted on glass slides and dried 
overnight.  These slides were then incubated in a 0.003% potassium permanganate solution for 
10 min.  After rinsing with water the sections were incubated from 1-2 min in a 2.0% oxalic acid 
solution then rinsed thoroughly in water.  Slides were then incubated in a 5.0% sodium 
metaperiodate solution for 5 min and again rinsed in water.  Slides were then treated with an 
alkaline silver iodide solution (1 M sodium hydroxide, 0.6 M potassium iodide, 0.053% silver 
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nitrate) for 1 min, then rinsed three times with a 0.5% acetic acid solution.  Staining was 
developed by combining solutions A (5% sodium carbonate), B (0.024 M ammonium nitrate, 
0.012 M silver nitrate, 0.003 M tungstosilicic acid), and C (0.024 M ammonium nitrate, 0.012 M 
silver nitrate, 0.003 M tungstosilicic acid, 0.25% formaldehyde) in a 2:1:1 ratio, adding B and C 
to solution A and incubating for 10-30 min.  The slides were then rinsed three times in 0.5% 
acetic acid, then water.  The slides were then incubated in gold tone for 3-4 min and again rinsed 
in water, then a 1% sodium thiosulphate solution for 5 min and a final rinse in water before they 
were dehydrated and coverslipped using DPX.   
2.3.22 Tissue imaging and quantification 
An Axio Scan.Z1 (Zeiss) slide scanning microscope was used to image all tissue.  Bright 
field analysis was performed using Zeiss Neuroquant IAE analysis software.  This program was 
used to outline regions of interest from the entire slide.  Then, thresholds were set manually until 
only positive cells, as determined by the analyzer, were selected with as little non-specific areas 
selected as possible.  Using the batch process option, the Area Ratio of positive cells within the 
regions of interest was automatically calculated for each stained group.  
2.4 Results 
2.4.1 CyP40 disaggregates tau amyloids 
To investigate the activity of PPIases on tau fibrils, we purified three Hsp90 co-
chaperones that possess PPIase activity: CyP40, FK506-binding protein (FKBP) 51, and 
FKBP52. Individual PPIases were incubated with fibrillized recombinant P301L tau for 3 hours, 
and Thioflavin T (ThT) fluorescence was measured periodically. CyP40 decreased ThT 
fluorescence, indicating a reduction in ß-sheet secondary structure (Figure 2.1A). It should be 
 
 
 
41 
 
 
noted that ThT signal was not entirely ablated indicating tau species formed still maintain beta-
sheet content. An additional ThT assay showed that this effect was concentration dependent, 
since increasing the molar ratio of CyP40 to tau fibrils further decreased ThT fluorescence 
(Figure S2.1). Moreover, we determined that tau did not re-aggregate after CyP40 was 
inactivated by Cyclosporin A (Figure S2.2). Furthermore, FKBP51 and FKBP52, despite having 
a more robust PPIase activity relative to CyP40 (Figure S2.3), did not lower amyloid content. 
This is possibly due to differential substrate binding between tau and PPIases as will be 
discussed later.  
We then further characterized the tau species formed following incubation with CyP40. 
CyP40 dramatically altered the morphology and reduced the size of tau fibrils as observed by 
transmission electron microscopy (TEM) (Figure 2.1B). We then utilized Nanoparticle Tracking 
Analysis (NTA) to analyze the particle size profile of recombinant tau fibrils in the presence of 
CyP40. While mature tau P301L fibrils exist as an array of particles up to 850 nm in size, CyP40 
co-incubated samples lacked particles greater than 150 nm in length (Figure 2.1C and 2.1D), 
corroborating the results of the ThT and TEM assays. CyP40 alone showed a minimal number of 
particles (Figure S2.4). To further confirm CyP40 disaggregase activity, we utilized an inducible 
tau cell model 205 capable of forming insoluble tau. sarkosyl-insoluble tau was reduced by the 
overexpression of CyP40 (Figure 2.1E and 2.1F). An AlamarBlue assay showed that CyP40 was 
not toxic in the iHEKP301L model (Figure S2.5), confirming insoluble tau reduction was not 
caused by CyP40-associated toxicity. Taken together, these data indicate that CyP40 is capable 
of disaggregating amyloid fibrils in vitro. 
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2.4.2 CyP40 converted tau from sarkosyl-insoluble to sarkosyl-soluble in vivo 
The capacity of CyP40 to lower insoluble tau levels was then evaluated in a mouse model 
of tauopathy. Hippocampi of rTg4510 mice were injected with AAV9-GFP or AAV9-CyP40 at 6 
months of age and were harvested at 8 months for biochemical and histological analyses (Figure 
2.2A, Figure S2.6). These ages were chosen so that the disaggregation activity of CyP40 on 
insoluble tau fibrils could be investigated. CyP40 and GFP protein expression was achieved 
throughout the hippocampus (Figure S2.6). CyP40 was expressed 9.2x higher in mice transduced 
with AAV9-CyP40 compared to GFP-injected control mice (Figure S2.7). CyP40 overexpression 
caused a significant decreased in the amount of sarkosyl-insoluble tau, while significantly 
increasing soluble tau levels (Figure 2.2B and 2.2C), suggesting CyP40 disaggregated insoluble 
tau in vivo. 
2.4.3 CyP40 reduced pathologically relevant tau, preserved neuron viability 
To further characterize the state of tau following CyP40 overexpression, 
immunohistochemical analyses were conducted. Transduction of CyP40 significantly reduced 
the levels of Gallyas silver-positive tau tangles (Figure 2.3A and 2.3B), a hallmark of 
tauopathies214,215. However, it has been suggested that soluble tau oligomers, like those 
recognized by T22 tau antibody 216, are more closely associated with neurodegeneration than tau 
tangles 122,206,217,218. To determine if the transition of tau from insoluble to soluble was producing 
toxic oligomers, we quantified the levels of T22-positive tau. CyP40 decreased T22-positive tau 
levels (Figure 2.3C and 2.3D) demonstrating that CyP40 can affect numerous multimeric tau 
species regardless of solubility. To determine if Cyp40 overexpression was neuroprotective, 
neuron counts were performed using unbiased stereology. CyP40 overexpression significantly 
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preserved CA1 neurons (Figure 2.3E and 2.3F), suggesting that CyP40 may disaggregate tau into 
non-toxic species.  
2.4.4 CyP40 overexpression rescued tau-induced cognitive deficits 
To evaluate the effects of CyP40 overexpression on learning and memory, rTg4510 and 
wild-type (WT) mice were injected with AAV9-GFP or AAV9-CyP40 at 3 months of age. 
CyP40 overexpressing rTg4510 mice showed a significant reduction in errors compared to GFP 
overexpressing rTg4510 mice in the two-day radial-arm water maze paradigm (Figure 2.4A). 
This reduction in errors suggests that spatial learning and memory is more intact in rTg4510 
mice overexpressing CyP40 219. Significant differences were not found in CyP40 or GFP 
overexpressing WT mice. Additionally, CyP40 overexpression in rTg4510 mice rescued tau-
induced freezing deficits in the cued fear conditioning task (Figure 2.4B). This increase in 
freezing is indicative of a preservation of associative learning and memory 220, suggesting CyP40 
disaggregated existing tau fibrils or prevented the accumulation of aggregating tau 
prophylactically. Collectively, these data suggest that CyP40 decreased tau aggregates, reduced 
toxic tau oligomers, increased neuronal survival, and improved cognitive function in vivo. 
2.4.5 CyP40 disaggregates α-synuclein but not ß-amyloid 
To investigate the potential for CyP40 to disaggregate amyloids other than tau, we 
generated recombinant fibrils of A53T α-synuclein (α-syn) and ß-amyloid1-42 (Aß42). Similar to 
tau, CyP40 decreased ThT fluorescence when incubated with α-synuclein fibrils (Figure 2.5A); 
TEM and NTA corroborated these results (Figure 2.5B, S2.8). Conversely, CyP40 was unable to 
disaggregate Aß42 fibrils (Figure 2.5C and 2.5D, and Figure S2.8). Both tau and α-synuclein 
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contain proline residues, Aß42 does not. This suggests CyP40 disaggregation activity is proline-
dependent, thus supporting a PPIase-dependent mechanism. 
2.4.6 CyP40 selectively binds proline-containing regions of tau and α-synuclein 
Next, we acquired 2D heteronuclear single quantum coherence (HSQC) spectra of 15N-
labeled α-synuclein and tau in the presence and absence of unlabeled CyP40. This provides a 
spectral signature encompassing all amide bonds within a protein, allowing us to map interaction 
sites by recording variations in position and/or intensity of individual peaks. Upon Cyp40 
addition to α-synuclein, the residues present at the C-terminus of the protein displayed a 
significant intensity loss together with changes in NMR signal position (Figure 2.6 A-C). In the 
case of tau, a subset of signals mostly contained in the proline-rich region were attenuated with 
increasing CyP40 concentration (Figure 2.6 D-F), indicating that the binding between the two 
proteins is specific to this region. The reduction in signal intensity in protein NMR is typically 
caused by the combined effects of an increase in molecular weight due to complex formation, 
which accelerates transverse relaxation and chemical exchange at the contact surface 221-223. The 
reduction in intensity seen here is consistent with an intermediate exchange time scale of CyP40-
tau binding. Based on these findings, CyP40 selectively recognized proline-rich regions in both 
proteins. Interestingly, proline-containing ß-turn structures are thought to be exposed in mature 
fibrils 224, providing a possible mechanism for how CyP40 accomplishes its disaggregation 
function. Conversely, HSQC spectra of both proteins in the presence of FKBP51, indicate that 
FKBP51 does not interact with monomeric α-synuclein (Figure 2.6 G-I) and suggests that 
FKBP51 binds to the microtubule binding region of tau instead of proline rich domains (Figure 
2.6J and 2.6K). This offers a possible explanation for the lack of FKBP51 disaggregation activity 
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relative to CyP40. To further support the need for CyP40 binding to the proline rich region of tau 
in order to disaggregate amyloid fibrils, CyP40 was incubated with fibrillized K18 fragment of 
tau consisting of only the microtubule binding domain repeats. CyP40 was unable to 
disaggregate this substrate (Figure 2.6L).  
2.4.7 CyP40-mediated disaggregation is diminished in a PPIase-null CyP40 mutant 
To further explore the mechanism of CyP40-mediated disaggregation, a mutant of CyP40 
lacking PPIase activity was constructed. Mutation of histidine 141 to glutamate (H141E) ablated 
PPIase activity as shown by a chymotrypsin-coupled assay (Figure S2.9). Importantly, the 
mutation did not significantly alter secondary structure of the protein as evidenced by circular 
dichroism (Figure S2.9). Wild-type (wt) and mutant (mut) CyP40 were incubated with tau P301L 
fibrils, and ThT fluorescence was recorded. Cyp40 lacking PPIase activity was unable to 
disaggregate tau fibrils (Figure 2.7A). Corresponding TEM showed fibril morphology was 
maintained following incubation with mut CyP40, while, as expected, wt CyP40 decreased 
fibrils (Figure 2.7B). Similarly, CyP40 PPIase activity was essential for A53T α-synuclein fibril 
disaggregation (Figure 2.7C and 2.7D).  Collectively, these data indicate that the PPIase activity 
of CyP40 is necessary for disaggregation activity in vitro. These findings also rule out the 
possibility that the disaggregation activity of CyP40 was the result of any technical artifacts 
caused by production or purification of recombinant proteins 225. 
We further explored the putative molecular mechanism of CyP40-mediated 
disaggregation through the analysis of its intrinsic disorder propensity and through available 
structural information. Structural data in the Protein Data Bank (PDB) is available only for 
bovine CyP40, which shares 93.78% sequence identity along with similar disorder plot profiles 
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to human CyP40 (Figure S2.10) Structural analysis of bovine CyP40 revealed that this protein 
can be crystallized in the monoclinic and tetragonal forms. These forms differ dramatically in the 
spatial organization of the C-terminal domain containing three tetratricopeptide (TPR) motifs 
(residues 223-256, 273-306, and 307-340) 226. Figure 2.8Aa shows that although the monoclinic 
form is characterized by the presence of seven α-helices of variable length (residues 216-235, 
239-259, 269-285, 289-300, 307-319, 323-336, and 341-362) packed in a relatively compact 
domain (PDB ID: 1ihg), the structure of tetragonal form (PDB ID: 1iip) is remarkably different 
(Figure 2.8Ab). Figure 2.8Ac shows that the structures of PPIase cyclophilin-type domain and 
TPR-1 motif remain mostly unperturbed. In fact, in multiple structural alignment, the RMSD for 
this region spanning residues 1-259 is remarkably low, 0.53 Å. On the other hand, two α-helices 
of TPR-2 have straightened out, and, together with the second helix of the TPR-1, form one 
extended α-helix (residues 239-297) that protrudes out from the protein. Furthermore, this 
structure does not contain coordinates for the C-terminal region of this protein (residues 298-
369) which includes the TPR-3 and the C-tail containing putative calmodulin binding site 226. 
Since the C-terminal half of CyP40 (residues 185-370) is responsible for the chaperone activity 
as well as the interaction with Hsp90 and several other binding partners, it was suggested that a 
partially folded form of the TPR-containing domain may be related to the functionality of this 
protein 226. The ability of CyP40 to undergo dramatic conformational changes from more closed, 
monoclinic-like structure to a widely open, tetragonal-like form (see Figure 2.8A) potentially 
resides in the specifics of the intrinsic disorder propensity distribution within its sequence. In 
agreement with this hypothesis Figure 2.8B shows that regions linking the PPIase and TPR-
containing domains and linkers between the individual TPR motifs are predicted to be either high 
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disordered (have disorder score above 0.5) or at least flexible (have disorder scores between 0.25 
and 0.5), thereby providing means for high conformational flexibility. Though the exact 
mechanism by which CyP40 disaggregates fibrils remains unclear, this is the first demonstration 
of a single human protein to display disaggregase activity both in vitro and in vivo. 
2.5 Discussion 
In this study, we describe the disaggregation activity of the human cyclophilin, CyP40. 
This is the first description of a PPIase disaggregating neurodegenerative amyloids, such as tau 
and α-syn. This disaggregation is dependent on the PPIase activity of CyP40 and is ATP-
independent. The distinct structural properties of CyP40 may enable this ATP-independent 
process to occur, and thus may be unique to CyP40 among other PPIases. Disaggregation of tau 
fibrils by CyP40 reduced pathogenic tau, concomitant with decreased neuronal toxicity and 
increased cognitive performance. 
While being the first human PPIase to display disaggregation activity, CyP40 is not the 
first disaggregase to be identified. Certain chaperone complexes have been shown to facilitate 
the disaggregation of oligomers and fibrils 20,225,227. For example, the Hsc70/DNAJB1/Apg2 
containing complex was shown to reverse the formation of α-syn fibrils in vitro. Identification of 
this complex was notable because, while previous attempts at chaperone-mediated amyloid 
disassembly required weeks of incubation in vitro 190, this complex solubilized α-syn fibrils in 
under an hour 20. Disaggregation by the Hsc chaperone complex required ATP, however, our 
study demonstrated that fibrils could be disaggregated with similar kinetics by CyP40 in the 
absence of ATP. Regardless of energy dependence, the existence of amyloid disaggregases 
presents a new avenue for therapeutic strategies. The pro-cognitive effects of CyP40 
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overexpression in the tauopathic brain suggests that strategies to either induce or deliver 
disaggregases to the central nervous system could halt or even rescue cognitive deficits 
associated with neurotoxic amyloids.  
We hypothesize two possible mechanisms for amyloid disaggregation by CyP40. Based 
on our structural data (Figure 2.8A), it is possible that the PPIase domain interacts with specific 
proline residues in β-turns and twists these residues. Given that CyP40-mediated disaggregation 
occurs without the input of external energy, it is possible that the disaggregation reaction energy 
comes from the PPIase domain of CyP40 binding to key residues within the amyloid substrate 
followed by a conformational switch within the TPR domain (Figure 2.8C). There is precedent 
for disaggregation independent of external energy as described for the plant chaperone, 
cpSRP43228. Due to the equimolar amount of substrate and CyP40 used in the ThT-monitored 
disaggregation experiments an alternative mechanism could be proposed. In this hypothesis, 
CyP40 may interact with and sequester small oligomers and monomers away from the 
aggregation equilibrium (see Figure 2.8D). However, this hypothesis does not explain the lack of 
disaggregation activity in the PPIase-null CyP40. Therefore, further experiments are required to 
determine the precise mechanism by which CyP40 disaggregation occurs.  
Though CyP40 can directly interact with Hsp90 through a TPR domain, the effects 
described here do not appear to be Hsp90-dependent. In fact, the PPIase activity of CyP40 is 
reduced upon interaction with Hsp90 201. This may explain that while CyP40 is expressed in our 
models of tauopathy, tau fibrils were only disaggregated upon the overexpression of CyP40; 
potentially providing a pool of free CyP40 to interact with amyloids. In addition to CyP40, there 
are currently 41 known human PPIases within the cyclophilin, FKBP and parvulin families. 
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Therefore, future screening may reveal additional PPIases with activities similar to CyP40, 
including ATP-independent disaggregation. Additionally, CyP40 and other PPIases should be 
further characterized for disaggregation activity against proline-containing amyloids, especially 
those associated with disease. 
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Figure 2.1 CyP40 disaggregated tau fibrils. (A) Preformed tau fibrils were monitored for 
Thioflavin T (ThT) fluorescence intensity over 4 h.  CyP40, FKBP51, FKBP52 were added at 1 
h and monitoring continued for 3 h (bars represent SEM, unpaired t-test, p = 0.0446, n=2 
independent protein preparations). (B) Representative 60,000x transmission electron microscopy 
(TEM) images of tau fibrils or CyP40-treated fibrils (scale bar 400 nm, n=2 independent 
preparations of recombinant protein). (C) Nanoparticle tracking analysis (NTA) size distribution 
of tau fibrils and CyP40-treated tau fibrils. (D) Representative images of particles from the NTA. 
(E) Inducible HEK cells overexpressing tau P301L (iHEKP301L) were induced with tetracycline 
on day 1 and transfected with either control vector or CyP40 on day 9. Sarkosyl-soluble and 
insoluble fractions were collected at day 11. Sarkosyl-insoluble fractions were probed by 
Western blot with Tau 12 antibody. Sarkosyl-soluble fractions were probed by Western blot with 
H-150 anti-tau, anti-CyP40 and anti-GAPDH antibodies. (F) Quantification of insoluble tau 
levels on day 11 (unpaired t-test, n=2 independent experiments). 
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Figure 2.2 CyP40 overexpression decreased sarkosyl-insoluble tau. (A) Schematic depicting 
the timeline of rTg4510 tau pathology and experimental design. (B) Western blot comparing 
sarkosyl-insoluble and soluble fractions from hippocampi of AAV9-GFP (n = 8) and AAV9-
CyP40 (n = 8) injected rTg4510 mice. Each lane indicates an individual transgenic mouse. (C) 
Quantification of the relative insoluble and soluble tau for AAV9-GFP and AAV9-CyP40 
injected mice (unpaired t-test, n = 8 for each group).  
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Figure 2.3 CyP40 reduced tau deposits and preserved hippocampal CA1 neurons in vivo 
(A) Representative images of Gallyas silver-stained hippocampi from AAV9-GFP and AAV9-
CyP40 injected mice (scale bar 200 µm). (B) Quantification of Gallyas silver-staining (unpaired 
t-test, n=8 for each group) (C) Representative images of T22-oligomeric tau stained hippocampi 
from AAV9-GFP and AAV9-CyP40 injected mice (scale bar 200 µm). (D) Quantification of 
T22-oligomeric tau staining (unpaired t-test, n=8 for each group) (E) Representative images of 
CA1 neurons stained with NeuN (brown) and Nissl (violet) are shown (scale bar 125 µm). (F) 
Neuron counts from unbiased stereology of CA1 neurons in hippocampal sections from AAV9-
GFP and AAV9-CyP40 injected mice (unpaired t-test, n=8 for each group). 
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Figure 2.4 CyP40 rescued tau-induced cognitive deficits (A) Radial-arm water maze spatial 
memory analysis of AAV9-GFP injected wildtype (wt) (n=9), AAV9-CyP40 injected wt (n=10), 
AAV9-GFP injected rTg4510 mice (n=9), AAV9-CyP40 injected rTg4510 mice (n=10). Data 
were analyzed by two-way ANOVA and significant results were followed by Tukey post hoc 
tests (*p < 0.05). (B) Percent freezing in the cued fear conditioning task (n=5 for each group). 
Data were analyzed by two-way ANOVA and significant results were followed by Tukey post 
hoc tests (*p < 0.05). 
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Figure 2.5 CyP40 disaggregated α-synuclein, but not Aβ42 fibrils. (A) ThT fluorescence of 
A53T α-synuclein (α-syn) fibrils ± CyP40 protein (unpaired t-test, n=4). (B) Representative 
TEM images of α-synuclein A53T fibrils ± CyP40 (60,000x magnification; scale bar 400 nm) 
(C) ThT fluorescence of Aβ42 fibrils ± CyP40 protein (unpaired t-test, n=4). (D) Representative 
TEM images of Aβ42 fibrils ± CyP40 (60,000x magnification; scale bar 400 nm). 
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Figure 2.6 CyP40 binds proline-containing regions of tau and α-synuclein. (A) A selected 
region of the 2D [1H-15N]-HSQC experiment of 15N-labeled α-synuclein before (blue) and after 
(red) addition of CyP40 (molar ratio 1:15). Y136 is marked. (B) Normalized residue-specific 
NMR intensities in the presence of a 5-fold (red) and 15-fold (blue) excess of Cyp40; the 
location of proline residues is indicated. (C) Combined [1H-15N] chemical shift perturbation 
analysis upon addition of CyP40 to α-synuclein. (D) A selected region of 2D [1H-15N]-HSQC 
experiment of tau before (blue) and after (red) addition of CyP40 (molar ratio 1:10) is shown. 
Residues displaying significant intensity loss are labeled. (E) Normalized residue-specific NMR 
intensities of tau in the presence of a 5-fold (red) and 10-fold (blue) excess of CyP40; tau’s 
domain organization is shown and proline residues are marked with red. (F) Amino acid 
sequence of the proline-rich regions P1 (top) and P2 (bottom); residues significantly broadened 
upon addition of CyP40 are colored red. (G) A selected region of the 2D [1H-15N]-HSQC 
experiment of 15N-labeled α-synuclein before (blue) and after (red) addition of FKBP51 (molar 
ratio 1:10) is displayed. (H) Normalized residue-specific NMR intensities in the presence of a 5-
fold (red) and 10-fold (blue) excess of FKBP51. (I) Combined [1H-15N] chemical shift 
perturbation analysis upon addition of FKBP51 to α-synuclein. (J) Selected region of a 2D [1H-
15N]-HSQC experiment of tau before (blue) and after (red) addition of FKBP51 (molar ratio 
1:10). Final concentrations of CyP40 and FKBP51 for NMR experiments are 200 µM. (K) Tau 
residue-specific NMR intensities in presence of a 10-fold excess of FKBP51. (L) Thioflavin T 
fluorescence of K18 tau aggregates in the presence or absence of CyP40 (unpaired t-test, p > 
0.05, n=3). 
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Figure 2.7 CyP40-mediated disaggregation assay of wt and PPIase null mutant CyP40 (A) 
Thioflavin T (ThT) fluorescence of tau ± wt CyP40 or mut CyP40 (unpaired t-test, n=3 for each 
condition). (B) Representative transmission electron microscopy (TEM) images of (A) (scale bar 
200 nm). (C) Thioflavin T (ThT) fluorescence of A53T α-synuclein (α-syn) ± wt CyP40 or mut 
CyP40 (unpaired t-test, n=3 for each condition). (B) Representative TEM images of (C) (scale 
bar 200 nm). 
 
 
 
57 
 
 
 
Figure 2.8 CyP40 conformation, disorder prediction, and putative disaggregase 
mechanisms. (A) Structural characterization of bovine CyP40: a, Crystal structure of the 
monoclinic form of CyP40 (PDB ID: 1ihg); b, Crystal structure of the tetragonal form of CyP40 
(PDB ID: 1iip). Structures in plots a and b are colored according to the secondary structure 
content; c, Multiple structural alignment of the monoclinic (blue) and tetragonal (red) forms of 
CyP40 conducted by MultiProt platform. (B) Evaluating intrinsic disorder propensity of human 
CyP40 (UniProt ID: Q08752) by series of per-residue disorder predictors. Disorder profiles 
generated by PONDR® VLXT, PONDR® VL3, PONDR® VSL2, IUPred_short, IUPred_long, 
and PONDR® FIT are shown by black, red, green, yellow, blue, and pink lines, respectively. 
Light pink shadow around the PONDR® FIT shows error distribution. Cyan shaded area shows 
position of the region with chaperone activity. Positions of three TPR motifs are shown as gray 
shaded areas. In these disorder analyses, the predicted intrinsic disorder scores above 0.5 are 
considered to correspond to the disordered residues/regions. (C) Schematic representation of 
hypothesized enzymatic activity-based CyP40 disaggregation. (D) Schematic representation of 
hypothesized interaction-based CyP40 disaggregation. 
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Figure S2.1 Ratio-dependent CyP40 tau disaggregation. Incubations of increasing molar 
ratios of CyP40 to tau fibrils, as indicated, were monitored by Thioflavin T fluorescence. 
Samples were run in triplicate (n = 3).  
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Figure S2.2 Inactivation of recombinant CyP40 with cyclosporin A (CsA) after 
disaggregation of tau fibrils. Cyclosporin A (dashed line) or DMSO (solid line) was 
administered to tau fibrils in the presence (red) or absence (black/grey) of CyP40 at 16 hours. 
Samples were run in duplicate (n = 2). 
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Figure S2.3 Chymotrypsin-coupled PPIase activity assay. Curves represent No Enzyme 
(black), CyP40 (red), FKBP51 (blue), FKBP52 (purple) incubated with chymotrypsin (6mg/mL, 
pH 8.0) and substrate (Suc-AAPF-pNA, 100uM) over 300s. (One-way ANOVA, p < 0.0001, n = 
2 independent preparations). 
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Figure S2.4 Nanoparticle tracking analysis of CyP40. Nanoparticle tracking analysis assay of 
buffer (green), 7.5uM CyP40 (red), and 15uM CyP40 (orange). 
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Figure S2.5 CyP40 did not reduce cell viability. iHekP301LP301L cell viability was monitored 
using an AlamarBlue assay following CyP40 (red) or vector (black) transfection ± tau induction 
by tetracycline. Results are expressed relative to vector without tau induction. Samples were run 
in triplicate (n = 3).  
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Figure S2.6 AAV9 hippocampal injections and expression. (A) AAV9-GFP (green) or 
AAV9-CyP40 (red) injection locations within the hippocampus are indicated. Hippocampal 
regions are denoted, CA1, CA2, CA3, and Dentate Gyrus (DG). (B) A representative images of 
AAV9-GFP and CyP40 expression in hippocampi 2 months post-injection (scale bar 200 μm). 
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Figure S2.7 Expression levels of CyP40 protein from individual mouse brain lysates. 
Western blot analysis of CyP40 expression in AAV9-GFP and AAV9-CyP40 injected mice are 
compared to a standard curve generated with recombinant CyP40 protein (ng quantities 
indicated). Each lane represents an individual mouse. Western blot probed with anti-CyP40 
antibody. 
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Figure S2.8 Nanoparticle analysis of α-synuclein and Aβ42 fibrils after CyP40 co-
incubation. (A) Nanoparticle tracking analysis size distribution of A53T α-synuclein fibrils ± 
CyP40. (B) Representative images of (A). (C) Nanoparticle tracking analysis size distribution of 
Aβ42 fibrils ± CyP40. (D) Representative images of particles of (C). 
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Figure S2.9 Nanoparticle analysis of α-synuclein and Aβ42 fibrils after CyP40 co-
incubation. (A) Coupled chymotrypsin assay of isomerase activity of wt CyP40 (red), mut 
CyP40 (teal), and No Enzyme (black) (n = 2 independent preparations). (B) Circular dichroism 
of wt CyP40 (red) and mut CyP40 (teal). 
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Figure S2.10 Nanoparticle analysis of α-synuclein and Aβ42 fibrils after CyP40 co-
incubation. 
(A) Evaluating intrinsic disorder propensity of human CyP40 (UniProt ID: Q08752) by a series 
of per-residue disorder predictors. (B) Evaluating intrinsic disorder propensity of bovine CyP40 
(UniProt ID: P26882). In these plots, disorder profiles generated by PONDR® VLXT, PONDR® 
VL3, PONDR® VSL2, IUPred_short, IUPred_long, and PONDR® FIT are shown by black, red, 
green, yellow, blue, and pink lines, respectively. Light pink shadow around the PONDR® FIT 
shows error distribution. (C) Comparison of the mean disorder propensity of human black solid 
curve) and bovine CyP40 (red dashed curve). In plots A, B, and C, cyan shaded area shows 
position of the region with chaperone activity. Positions of three TPR motifs are shown as gray 
shaded areas. In these disorder analyses, the predicted intrinsic disorder scores above 0.5 are 
considered to correspond to the disordered residues/regions. (D) Pairwise sequence alignment of 
human and bovine CyP40 proteins (UniProt IDs Q08752 and P26882, respectively). Identical 
residues are indicated by star symbol, whereas colon and period symbols show similar residues. 
Sequences are colored according to the major physic-chemical properties of their residues, with 
red and green symbols corresponding to hydrophobic and polar residues, respectively, and with 
positively and negatively charged residues shown by pink and blue symbols, respectively. 
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CHAPTER THREE: 
 
FUTURE STUDIES AND FINAL CONSIDERATIONS 
 
3.1 Introduction 
 
Although the previous study demonstrating the disaggregase capacity of cyclophilin 40 
(CyP40) is exciting, further work is needed to answer several key questions. This chapter will 
discuss a number of continuing studies designed to provide mechanistic insight into CyP40 
disaggregation, provide putative strategies to increase the disaggregase activity of CyP40, to 
evaluate the end products of CyP-40 mediated disaggregation, and finally will discuss the 
challenges in moving forward with therapeutic CyP40-mediated tau reduction. 
3.2 Mechanistic questions 
CyP40 belongs to an immunophilin subfamily known as cyclophilins. In an effort to 
determine if disaggregase activity was unique to CyP40, we performed an in vitro assay 
measuring thioflavin T fluorescence over a 16-hour time period for several cyclophilins 
incubated with mature tau fibrils (Figure 3.1). Our data suggests that CyP40 disaggregation 
activity is unique within the cyclophilin 40 family, as it was the only cyclophilin able to 
disaggregate tau fibers and maintain lowered amyloid content over an extended timeframe. 
Interestingly, PPIE, another prolyl-isomerase reduced amyloid content of tau fibrils, but only 
briefly. This suggests that this enzyme may disaggregate fibrils into unstable oligomers which 
readily reaggregate. Further follow-up studies including electron microscopy, size-exclusion 
chromatography and standard toxicity assays are needed to elucidate end product differences 
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resulting from disaggregation by these two prolyl-isomerases. Additionally, data from 
Alzheimer’s patients reveals that CyP40 may have a physiological role in AD, as mRNA levels 
are lower in AD brains compared to non-demented controls, specifically in the entorhinal cortex 
(Figure 3.2). 
As of now, we have little insight into the mechanism of CyP40-mediated tau disaggregation. 
Our screen of cyclophilins provides evidence that the prolyl-isomerase activity of CyP40 is not 
sufficient to disaggregate amyloid substrates, as PPIA, which consists of solely the prolyl-
isomerase domain of CyP40 is devoid of disaggregase activity. To this end, we propose 
generating a series of constructs consisting of CyP40 truncations in order to pin-point domains 
required for disaggregation. CyP40 is composed of an N-terminal PPIase domain, a short linker 
domain, and finally a TPR domain that allows interaction with Hsp90. We will generate 
constructs consisting only of the proly-isomerase domain of CyP40 with or without the linker 
domain as well as the C-terminal TPR domain as illustrated in Figure 3.3. We will then test the 
disaggregase propensity for each of these constructs using previously discussed assays including 
thioflavin t fluorescence, electron microscopy, and human cell models. Further studies will be 
required to determine enzymatic residues responsible for disaggregation within associated 
protein domains. 
 Additionally, although our work described the activity of CyP40 with mature tau fibers, 
we have not demonstrated its affinity for different aggregation states of tau including oligomers. 
To this end, we will incubate tau oligomers with CyP40 in order to determine the interaction 
potential as well as to assess CyP40 effect on oligomeric toxicity. This will be evaluated by 
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externally applying CyP40-treated or untreated oligomeric tau to neuronal cells in vitro and by 
measuring toxicity through standard assays including LDH enzymatic activity. 
 Finally, as of now, we do not know the tau fiber residues required for CyP40-mediated 
disaggregation. To answer this question, we will mutate key prolines within the aggregation and 
proline rich domains of tau (Table 3.1) and test for CyP40 binding by NMR-analysis and 
disaggregation activity by thioflavin t fluorescence and electron microscopy. 
3.3 Engineering a better disaggregase 
A future goal of these studies is to engineer a powerful disaggregase capable of therapeutic 
applications in neurodegenerative disorders including Alzheimer’s disease and other tauopathies. 
We will therefore attempt to increase disaggregation activity by generating chimeric constructs 
consisting of various prolyl-isomerase domains of other cyclophilins (See Figure 3.3) and testing 
for disaggregase activity as previously described in this manuscript. A chymotrypsin-coupled 
assay measuring prolyl-isomerase activity shows that cyclophilin family members present 
differing enzymatic activity (Figure 3.4), so this recombination may impact disaggregation. 
Finally, as an alternative approach, random mutagenesis of CyP40 along with a high-throughput 
disaggregation screen may be invaluable in increasing enzymatic activity or substrate recognition 
of the disaggregase. The therapeutic challenge for CyP40 arises from a need to upregulate its 
activity specifically in brain tissue. Although gene therapy capable of delivering an enhanced 
enzyme directly is possible, recent work has shown that when not bound to Hsp90, CyP40 
activity is increased. To this end, we propose screening for small molecules specifically capable 
of inhibiting the interaction of CyP40 and Hsp90, and to follow up a series of studies for 
inhibitor toxicity and in vivo and in vitro assays of disaggregation within inhibitor treatment. 
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3.4 Overall conclusions 
Work within this manuscript has provided strong evidence for CyP40 as a disaggregase with 
substrate recognition toward amyloid substrates including tau and α-synuclein. The major 
findings presented herein are that CyP40 disaggregates mature tau fibers in vitro, as shown by 
multiple methods including thioflavin T fluorescence, transmission electron microscopy, and 
nanoparticle tracking analysis. Furthermore, for the first time, overexpression of this 
disaggregase was shown to reduce insoluble tau in a human cell model of tauopathy. Finally, a 
major discovery presented here is the capacity for CyP40 overexpression to decrease insoluble 
tau load, preserve neurons, and rescue behavioral deficits in a mouse model of tauopathy.  
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Figure 3.1 A disaggregase assay of various cyclophilins. 
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Figure 3.2 CyP40 mRNA levels in entorhinal cortex and hippocampus in young, aged, and 
Alzheimer’s disease brains. 
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Figure 3.3 CyP40 truncations and chimeras 
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Figure 3.4 Prolyl-isomerase enzymatic activity assay. 
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Table 3.1 Tau Proline Mutations 
Tau Proline Residue Mutations 
P203A 
P216A 
P221A 
P232A 
P233A 
P236A 
P301A 
P312A 
P332A 
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